PTGS2 and colorectal carcinoma: Moreover and interestingly, in a trial by Enric Domingo and colleagues published in 2013, patients with PIK3CA-mutated CRC benefited from aspirin, albeit no improvement was seen in the patients being treated with the COX-2-inhibitor rofecoxib [34].